# Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

> **NCT07661459** · PHASE2 · RECRUITING · sponsor: **Val Adams** · enrollment: 98 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Asprin
- **DRUG:** Loratadine
- **BEHAVIORAL:** Acetaminophen Avoidance
- **BEHAVIORAL:** THC Avoidance

## Key facts

- **NCT ID:** NCT07661459
- **Lead sponsor:** Val Adams
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-26
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661459, "Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07661459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*